1334719-95-7 Usage
General Description
Q203, also known as TMC-207, is a potent and selective inhibitor of the mycobacterial respiratory cytochrome bc1 complex, which is essential for the growth and survival of Mycobacterium tuberculosis, the bacteria that causes tuberculosis. Q203 has demonstrated strong anti-tubercular activity in preclinical studies, with the potential to overcome resistance to existing drugs. Q203 has been shown to inhibit the growth of drug-sensitive and drug-resistant strains of M. tuberculosis, and it displays synergistic effects when combined with other anti-tubercular agents. Clinical trials have shown promising results, and Q203 is being investigated as a potential treatment for drug-resistant tuberculosis. Overall, Q203 has shown great promise as a novel and effective anti-tubercular agent with the potential to address the growing problem of drug-resistant tuberculosis.
Check Digit Verification of cas no
The CAS Registry Mumber 1334719-95-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,4,7,1 and 9 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1334719-95:
(9*1)+(8*3)+(7*3)+(6*4)+(5*7)+(4*1)+(3*9)+(2*9)+(1*5)=167
167 % 10 = 7
So 1334719-95-7 is a valid CAS Registry Number.
1334719-95-7Relevant articles and documents
Cobalt-Catalyzed Electrophilic Amination of Aryl- and Heteroarylzinc Pivalates with N-Hydroxylamine Benzoates
Chen, Yi-Hung,Gra?l, Simon,Knochel, Paul
, p. 1108 - 1111 (2018/01/01)
Aryl- and heteroarylzinc pivalates can be aminated with O-benzoylhydroxylamines at 25 °C within 2–4 h in the presence of 2.5–5.0 % CoCl2?2 LiCl to furnish the corresponding tertiary arylated or heteroarylated amines in good yields. This electrophilic amination also provides access to diarylamines and aryl(heteroaryl)amines. A new tuberculosis drug candidate (Q203) was prepared in six steps and 56 % overall yield by using this cobalt-catalyzed amination as the key step.
ANTI-INFECTIVE COMPOUNDS
-
Page/Page column 126, (2011/10/10)
The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
